- Patients
- Clinical Research
- Clinical trials
- BeiGene BGB-11417-301
Lymphoma
BeiGene BGB-11417-301
A phase 3, open-label, randomized study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) compared with Venetoclax plus Obinutuzumab in patients with previously untreated chronic lymphocytic leukemia
Trial overview
Malignant Haemotology
Lymphoma
III
Registration number: NCT06073821
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comDisclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.